Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W K Kelly

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2012
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaG T Gibney, S A Aziz, R L Camp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tractP M Dodd, J A McCaffrey, S Hilton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castrationO Smaletz, M Galsky, H I Scher, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Cancer|March 10, 2001
The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinomaE J Sherman, D G Pfister, H S Ruchlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancerP Sabbatini, S M Larson, A Kremer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancerW K Kelly, T Curley, S Slovin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancerS Halabi, S Dutta, C M Tangen, et al.
The Journal of Urology|April 7, 2020
Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate CancerJ Woo, S Santasusagna, J Banks, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2012
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaG T Gibney, S A Aziz, R L Camp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tractP M Dodd, J A McCaffrey, S Hilton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castrationO Smaletz, M Galsky, H I Scher, et al.
Cancer|March 30, 2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedulesD F Bajorin, J A McCaffrey, P M Dodd, et al.
Cancer|March 10, 2001
The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinomaE J Sherman, D G Pfister, H S Ruchlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancerP Sabbatini, S M Larson, A Kremer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancerW K Kelly, T Curley, S Slovin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 15, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancerS Halabi, S Dutta, C M Tangen, et al.
The Journal of Urology|April 7, 2020
Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate CancerJ Woo, S Santasusagna, J Banks, et al.
Pageof 4